Antiphospholipid Antibodies in Patients with Cancer

Abstract

Antiphospholipid antibodies are generally associated with Antiphospholipid Syndrome, which can occur as a primary disorder or may be secondary to connective tissue disease or tumour. The presence of antiphospholipid antibodies in patients with tumour disease is responsible for thrombotic complications. In a population of 53 tumor patients with positive carcinoembryonic antigen CEA, carbohydrate antigen CA19.9, CA125 and CA15.3 markers, IgM and IgG anticardiolipin and antiphosphatidylinositol were detected by solid-phase immunoassays. Our results show that moderate or high levels of antiphospholipid antibodies are present in a great number of patients with CEA and CA19.9 markers, suggesting a specific association with gastroenteric tumors. By testing for antiphosphatidylinositol antibodies, many patients not evidenced by the standard anticardiolipin assay were found to be antiphospholipid-positive. The analysis of antiphosphatidylinositol antibodies as a diagnostic tool in gastroenteric cancer to highlight patients with the risk of thromboembolic complications is discussed.

Triple Positive Antiphospholipid Syndrome in a Patient with Rectosigmoid Colon Cancer- a Rare Occurrence

“…Some reports have also demonstrated an association between gastrointestinal cancers, such as gastric signet ring cell adenocarcinoma and aPL [5]. A previous study showed that moderate-to-high levels of antiphospholipid antibodies were present in a sample of 53 patients with positive CEA and CA19-9 tumor markers, suggesting a possible association with gastrointestinal tumors [6]. Here, we report the rare case of a patient with APS in the presence of invasive adenocarcinoma of the rectosigmoid colon.…”

IgA Anticardiolipin in Patients with Gastroenteric Tumor

“…IgA-IgG-and IgM-aCL were done by kits for Elisa test (Alfa Wassermann, Alanno, Pescara, Italy) as previously reported [20] and have been repeated three times; similar results were obtained.…”

“…The presence of these antibodies in the diagnosis of tumor disease is correlated with high risk of developing thrombotic complications [19] which represent a significant cause of morbidity and mortality in cancer patients. Interestingly, it is has been highlighted that high levels of IgM and IgG aCL antibodies are produced only in the patients affected with gastroenteric tumor that have high level of CA19.9+ and CEA-CA19.9+, and not in patients with ovary and breast tumor [20]. So far there are no data regarding the possible role and production of IgA aCL in the patients with gastroenteric tumor, especially for the role of IgA immunization in the intestinal mucosa.…”

Investigation of a screening programme and the possible identification of biomarkers for early disseminated histiocytic sarcoma in Bernese Mountain dogs

“…Biomarkers can be either fluid or tissue‐based molecules that along with other diagnostic approaches may increase the precision of a correct diagnosis. In humans, several serum tumour markers have been detected including prostate serum antigen, 9 carcinoembryogenic antigen, 10 different carbohydrate antigen (CA) 125, CA19.9, CA15.3, 11–13 α ‐fetoprotein, 14 human chorionic gonadotro‐phin 15 and lactate dehydrogenase (LDH) 15 . Unfortunately, none of the markers are specific for cancer or pathognomic for a specific disease but they may act as important supplementary tests with more conventional diagnostics.…”